<DOC>
	<DOC>NCT00265018</DOC>
	<brief_summary>This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.</brief_summary>
	<brief_title>HD10 for Early Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Hodgkin´s lymphoma (histologically proven) CS (PS) IA, IB, IIA,IIB without any of the following risk factors: 1. bulky mediastinal mass (&gt; 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR &gt; 50 (A), &gt; 30 (Bsymptoms) 4. 3 or more lymph node areas involved written informaed consent Leukocytes &lt;3000/microl Platelets &lt;100000/microl Hodgkin´s Disease as "composite lymphoma" Activity index (WHO) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s lymphoma</keyword>
	<keyword>early stages</keyword>
</DOC>